The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?

Jordi Remon^*, Lizza E L Hendriks, Martin Reck

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

99 Downloads (Pure)

Original language	English
Article number	JCO2201737
Pages (from-to)	1176-1179
Number of pages	5
Journal	Journal of Clinical Oncology
Volume	41
Issue number	6
Early online date	3 Nov 2022
DOIs	https://doi.org/10.1200/jco.22.01737
Publication status	Published - 20 Feb 2023

Access to Document

@article{bd93e17807064b1a8c607d0f07e89b5b,

title = "The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?",

author = "Jordi Remon and Hendriks, {Lizza E L} and Martin Reck",

year = "2023",

month = feb,

day = "20",

doi = "10.1200/jco.22.01737",

language = "English",

volume = "41",

pages = "1176--1179",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "6",

}

TY - JOUR

T1 - The POSEIDON Trial

T2 - Will Secondary End Points Change Our Clinical Practice?

AU - Remon, Jordi

AU - Hendriks, Lizza E L

AU - Reck, Martin

PY - 2023/2/20

Y1 - 2023/2/20

U2 - 10.1200/jco.22.01737

DO - 10.1200/jco.22.01737

M3 - Editorial

C2 - 36331243

SN - 0732-183X

VL - 41

SP - 1176

EP - 1179

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 6

M1 - JCO2201737

ER -